Wang F, Finnin J, Tait C, et al. The Hydrolysis of Diclofenac Esters: Synthetic Prodrug Building Blocks for Biodegradable Drug-Polymer Conjugates. J Pharm Sci. 2016 Feb;105(2):773-785. doi: 10.1002/jps.24665. Epub 2016 Jan 29. PMID: 26540508.
Hart E, Azzopardi K, Taing H, et al. Efficacy of antimicrobial polymer coatings in an animal model of bacterial infection associated with foreign body implants. J Antimicrob Chemother. 2010 May;65(5):974-80. doi: 10.1093/jac/dkq057. Epub 2010 Mar 16. PMID: 20233779.
PolyActiva is developing products based on its proprietary Prezia technology and through a series of patent filings has a comprehensive intellectual property portfolio to protect them throughout the major jurisdictions.
PolyActiva’s portfolio currently has 8 active patent families comprising over 120 granted patents and a further 34 applications pending (as of 30 September 2023).
PolyActiva’s glaucoma program is specifically protected by 4 patent families with 31 granted patents and a further 33 pending applications.
Additional filings are ongoing.